Alnylam Pharmaceuticals | ALNY - Interest Income


Alnylam Pharmaceuticals reported $28.68M in Interest Income for its fiscal quarter ending in September of 2025.





Interest Income Change Date
Acadia Pharmaceuticals USD 8.25M 1M Sep/2025
Agios Pharmaceuticals USD 13.37M 1.14M Sep/2025
Alnylam Pharmaceuticals USD 28.68M 1.19M Sep/2025
Arrowhead Research USD 9.05M 1.97M Sep/2025
BioCryst Pharmaceuticals USD -0.13 3.59M Dec/2024
BioMarin Pharmaceutical USD 17.85M 973K Sep/2025
Incyte USD 30.75M 3.97M Dec/2025
Ionis Pharmaceuticals USD -0.66 0.29 Dec/2024
Moderna USD 73M 8M Sep/2025
Regeneron Pharmaceuticals USD 175.1M 300K Sep/2025
Sanofi EUR 114M 38M Sep/2025
Sarepta Therapeutics USD 8.38M 1.24M Sep/2025
Takeda JPY 87.87B 43.48B Dec/2025
Tectonic Therapeutic USD 1.74M 217K Dec/2024
Ultragenyx Pharmaceutical USD 5.86M 69K Sep/2025
Vertex Pharmaceuticals USD 125.7M 3.3M Sep/2025
Xencor USD 6.54M 710K Sep/2025